Bone densitometry is not a good predictor of hip fractureForAgainstBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7316.795 (Published 06 October 2001) Cite this as: BMJ 2001;323:795
Bone densitometry is not a good predictor of hip fracture
Bone densitometry is widely used in osteoporosis clinics to identify people at increased risk of fracture. Terence Wilkin and Devasenan Devendra believe that evidence for the efficacy of bone densitometry is weak, but Jan Dequeker and Frank P Luyten argue that their interpretation of the evidence is too narrow and that screening high risk patients is cost effective
- Terence J Wilkin, professor of medicine (T.Wilkin@plymouth.ac.uk),
- Devasenan Devendra, specialist registrar
- Department of Medicine, Postgraduate Medical School, Derriford Hospital, Plymouth PL6 8DH
- Department of Rheumatology, Universitaire Ziekenhuizen K U Leuven, B-3000 Leuven, Belgium
- Correspondence to: T J Wilkin
- Accepted 6 April 2001
The World Health Organization defines osteoporosis as a “progressive systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.”1 The low bone mass used to define osteoporosis is arbitrarily fixed at 2.5 standard deviations or more below the mean bone density for premenopausal women. Assessment of bone density provides a precise figure to which doctors and patients feel able to relate with confidence. We believe this confidence is unjustified.
By one definition, osteoporosis is an arbitrary point on a scale. By another, it is a pathological process of microarchitectural deterioration in which the unconstrained activity of bone osteoclasts accelerates bone resorption. The two definitions are fundamentally different. Accelerated bone resorprtion exists throughout postmenopausal life, whereas osteoporosis does not—and may never. Bone densitometry measures bone density, not bone turnover or bone stability. We have argued previously that bone turnover, rather than bone density, is the responsive element in treatments for preventing fractures.2 The pathology of osteoporosis is one of uncontrolled bone resorption and the treatment (whether hormone replacement therapy or bisphosphonates) antiresorptive. We present five evidence based reasons why the results of bone densitometry may not predict postmenopausal fracture of the hip in the way that many believe it to.
Hip fracture is rare before age 65
The purpose of measuring bone density is to direct preventive treatments towards those who would most benefit. Drug treatment is principally antiresorptive and it clearly reduces …
Correspondence to: J Dequeker
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial